Biogen has halved the price of its Alzheimer’s drug Aduhelm after sales fell short of expectations because insurers have been reluctant to pay for the treatment.
The Massachusetts-based biotech said it would now charge a list price of $28,200 a year for a patient of average weight.
Aduhelm was the first Alzheimer’s treatment approved in the US in decades that is designed to slow the development of the neurological disease. But experts have been divided over whether the benefits of the drug are significant. The US regulator’s scientific advisers voted against approval and a key European panel recently signalled that it was unlikely to approve the drug.
您已阅读39%（658字），剩余61%（1024字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。